Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Down to $3.01

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) gapped down before the market opened on Monday . The stock had previously closed at $3.01, but opened at $2.84. Lyell Immunopharma shares last traded at $2.58, with a volume of 191,586 shares.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their price objective on Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, February 29th.

Lyell Immunopharma Stock Performance

The business has a fifty day simple moving average of $2.25 and a 200 day simple moving average of $2.00.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $4.96 million. Lyell Immunopharma had a negative return on equity of 32.67% and a negative net margin of 180,486.14%. On average, sell-side analysts predict that Lyell Immunopharma, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Lyell Immunopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. WuXi AppTec Co. Ltd. bought a new position in shares of Lyell Immunopharma in the fourth quarter valued at approximately $15,871,000. Vanguard Group Inc. grew its holdings in shares of Lyell Immunopharma by 309.6% in the first quarter. Vanguard Group Inc. now owns 8,778,702 shares of the company’s stock valued at $44,332,000 after acquiring an additional 6,635,614 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Lyell Immunopharma by 290.6% in the first quarter. BlackRock Inc. now owns 7,809,490 shares of the company’s stock valued at $39,438,000 after acquiring an additional 5,810,038 shares in the last quarter. State Street Corp grew its holdings in shares of Lyell Immunopharma by 107.2% in the third quarter. State Street Corp now owns 5,379,838 shares of the company’s stock valued at $39,434,000 after acquiring an additional 2,783,919 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Lyell Immunopharma by 397.4% in the first quarter. Northern Trust Corp now owns 1,052,410 shares of the company’s stock valued at $5,315,000 after acquiring an additional 840,833 shares in the last quarter. 66.05% of the stock is owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.